GSK plc (LSE/NYSE: GSK) today announced positive topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, reactogenicity and safety of AREXVY (Respiratory ...
On several key measures of the fundamental soundness of a business, GSK looks in great shape to me. Over the first half of this year, sales rose 12%, to £15.247bn. Core operating profit jumped 22% ...
Len Friedland, MD, Vice President of Scientific Affairs and Public Health, GSK, said: “We are excited to share data on the co‑administration of our RSV and shingles vaccines. Adult ...
Some results have been hidden because they may be inaccessible to you